Evercore ISI analyst Umer Raffat initiated coverage of Metsera (MTSR) with an Outperform rating. Metsera has a full portfolio of GLP-1 programs in clinical development and its GPL-1 peptide has a long half life, which could enable monthly dosing, the analyst tells investors. Given the long half life of its GLP-1 peptide and slightly improved bioavailability of its oral peptide delivery technolgy, Metsera’s “API math for oral is quite reasonable/doable,” the analyst argues.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MTSR:
- Metsera, Inc.: Buy Rating Affirmed Due to Innovative Obesity Market Approach and Strong Growth Catalysts
- Metsera initiated with a Buy at BofA
- Metsera, Inc.: A Promising Buy in the Obesity Market with Potential for Significant Returns
- Metsera initiated with a Buy at Guggenheim
- Metsera initiated as Early-Stage Biotech at Goldman Sachs